Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate

Current Neuropharmacology

Volumn 6, Issue 4, 2008, Pages 379-385

  Volz, Trent J ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Dopamine; Dopamine transporter; Methamphetamine; Methylphenidate; Neuroprotection; Neurotoxicity; Parkinson's disease; Vesicular monoamine transporter 2

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMFEBUTAMONE; AMFONELIC ACID; AMPHETAMINE; BENZATROPINE; COCAINE DERIVATIVE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ETICLOPRIDE; LOBELINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; QUINPIROLE; REACTIVE OXYGEN METABOLITE; RESERPINE; VESICULAR MONOAMINE TRANSPORTER 2;

ATTENTION DEFICIT DISORDER; CELL TRANSPORT; CELL VACUOLE; CYTOPLASM; DEGENERATIVE DISEASE; DISTRESS SYNDROME; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; HUMAN; LOW DRUG DOSE; NARCOLEPSY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; UPREGULATION;

EID: 66149114444     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015908787386041     Document Type: Review

References (78)

1. Brandle, E., Fritzsch, G., Greven, J. (1992) Affinity of different local anesthetic drugs and catecholamines for the contraluminal transport system for organic cations in proximal tubules of rat kidneys. J. Pharmacol. Exp. Ther., 260, 734-741.
2. Brown, J.M., Hanson, G.R., Fleckenstein, A.E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem., 74, 2221-2223.
3. Brown, J.M., Yamamoto, B.K. (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol. Ther., 99, 45-53.
4. Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Gehlert, D.R., Perry, K.W. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711.
5. Cadet, J.L., Brannock, C. (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int., 32, 117-131.
6. Carroll, F.I., Lewin, A.H., Boja, J.W., Kuhar, M.J. (1992) Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem., 35, 969-981.
7. Challman, T.D., Lipsky, J.J. (2000) Methylphenidate: its pharmacology and uses. Mayo Clin. Proc., 75, 711-721.
8. Cubells, J.F., Rayport, S., Rajendran, G., Sulzer, D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci., 14, 2260-2271.
9. Devos, D., Krystkowiak, P., Clement, F., Dujardin, K., Cottencin, O., Waucquier, N., Ajebbar, K., Thielemans, B., Kroumova, M., Duhamel, A., Destee, A., Bordet, R., Defebvre, L. (2007) Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 78, 470-475.
10. Eyerman, D.J., Yamamoto, B.K. (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter-2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther., 312, 160-169.
11. Fernandez, F., Adams, F. (1986) Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg., 8, 296-300.
12. Fernandez, F., Levy, J.K., Samley, H.R., Pirozzolo, F.J., Lachar, D., Crowley, J., Adams, S., Ross, B., Ruiz, P. (1995) Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int. J. Psychiatry Med., 25, 53-67.
13. Fleckenstein, A.E., Volz, T.J., Riddle, E.L., Gibb, J.W., Hanson, G.R. (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol., 47, 681-698.
14. Fleming, S.M., Delville, Y., Schallert, T. (2005) An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behav. Brain Res., 156, 201-213.
15. Froimowitz, M., Patrick, K.S., Cody, V. (1995) Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT. Pharm. Res., 12, 1430-1434.
16. Fumagalli, F., Gainetdinov, R.R., Valenzano, K.J., Caron, M.G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci., 18, 4861-4869.
17. Fumagalli, F., Gainetdinov, R.R., Wang, Y.M., Valenzano, K.J., Miller, G.W., Caron, M.G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci., 19, 2424-2431.
18. Greenhill, L.L. (1992) Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am., 15, 1-27.
19. Gulaboski, R., Cordeiro, M.N., Milhazes, N., Garrido, J., Borges, F., Jorge, M., Pereira, C.M., Bogeski, I., Morales, A.H., Naumoski, B., Silva, A.F. (2007) Evaluation of the lipophilic properties of opioids, amphetamine-like drugs, and metabolites through electrochemical studies at the interface between two immiscible solutions. Anal. Biochem., 361, 236-243.
20. Heron, C., Costentin, J., Bonnet, J.J. (1994) Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur. J. Pharmacol., 264, 391-398.
21. Hogan, K.A., Staal, R.G., Sonsalla, P.K. (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem., 74, 2217-2220.
22. Jenner, P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord., 13, 24-34.
23. Johnson, C.J., Auger, W.R., Fedullo, P.F., Dimsdale, J.E. (1995) Methylphenidate in the 'hard to wean' patient. J. Psychosom. Res., 39, 63-68.
24. Jones, S.R., Gainetdinov, R.R., Wightman, R.M., Caron, M.G. (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci., 18, 1979-1986.
25. Kim, S., Westphalen, R., Callahan, B., Hatzidimitriou, G., Yuan, J., Ricaurte, G.A. (2000) Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. J. Pharmacol. Exp. Ther., 293, 625-633.
26. Kuczenski, R., Segal, D.S. (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem., 68, 2032-2037.
27. Larsen, K.E., Fon, E.A., Hastings, T.G., Edwards, R.H., Sulzer, D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci., 22, 8951-8960.
28. Liang, N.Y., Rutledge, C.O. (1982) Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol., 31, 983-992.
29. Liu, G. (2003) Presynaptic control of quantal size: kinetic mechanisms and implications for synaptic transmission and plasticity. Curr. Opin. Neurobiol., 13, 324-331.
30. Ludolph, A.G., Schaz, U., Storch, A., Liebau, S., Fegert, J.M., Boeckers, T.M. (2006) Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J. Neural. Transm., 113, 1927-1934.
31. Marek, G.J., Vosmer, G., Seiden, L.S. (1990) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res., 513, 274-279.
32. Markowitz, J.S., DeVane, C.L., Pestreich, L.K., Patrick, K.S., Muniz, R. (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J. Child Adolesc. Psychopharmacol., 16, 687-698.
33. Mayfield, R.D., Zahniser, N.R. (2001) Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol. Pharmacol., 59, 113-121.
34. Meiergerd, S.M., Patterson, T.A., Schenk, J.O. (1993) D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem., 61, 764-767.
35. Mitler, M.M., Aldrich, M.S., Koob, G.F., Zarcone, V.P. (1994) Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep, 17, 352-371.
36. Mitler, M.M., Hajdukovic, R., Erman, M., Koziol, J.A. (1990) Narcolepsy. J. Clin. Neurophysiol., 7, 93-118.
37. Morciano, M., Burre, J., Corvey, C., Karas, M., Zimmermann, H., Volknandt, W. (2005) Immunoisolation of two synaptic vesicle pools from synaptosomes: a proteomics analysis. J. Neurochem., 95, 1732-1745.
38. Nielsen, J.A., Chapin, D.S., Moore, K.E. (1983) Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rats. Life Sci., 33, 1899-1907.
39. O'Hara, C.M., Uhland-Smith, A., O'Malley, K.L., Todd, R.D. (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J. Pharmacol. Exp. Ther., 277, 186-192.
40. Panizzon, L. (1944) La preparazione di piridil- e piperidilarilacetonitrill e di alcuni productti di transformazione. Helv. Chim. Acta, 27, 1748-1756.
41. Patrick, K.S., Caldwell, R.W., Ferris, R.M., Breese, G.R. (1987) Pharmacology of the enantiomers of threo-methylphenidate. J. Pharmacol. Exp. Ther., 241, 152-158.
42. Porras, S.P., Jyske, P., Riekkola, M., Kenndler, E. (2001) Mobility and ionization constant of basic drugs in methanol. Applicaton of nonaqueous background electrolytes for capillary zone electrophoresis based on a conventional pH scale. J. Microcolumn Sep., 13, 149-155.
43. Riddle, E.L., Topham, M.K., Haycock, J.W., Hanson, G.R., Fleckenstein, A.E. (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol., 449, 71-74.
44. Rizzoli, S.O., Betz, W.J. (2004) The structural organization of the readily releasable pool of synaptic vesicles. Science, 303, 2037-2039.
45. Rizzoli, S.O., Betz, W.J. (2005) Synaptic vesicle pools. Nat. Rev. Neurosci., 6, 57-69.
46. Sandoval, V., Riddle, E.L., Hanson, G.R., Fleckenstein, A.E. (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther., 304, 1181-1187.
47. Sandoval, V., Riddle, E.L., Hanson, G.R., Fleckenstein, A.E. (2002) Methylphenidate redistributes vesicular monoamine transporter-2: Role of dopamine receptors. J. Neurosci., 22, 8705-8710.
48. Schenk, J.O. (2002) The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog. Drug Res., 59, 111-131.
49. Schweri, M.M., Skolnick, P., Rafferty, M.F., Rice, K.C., Janowsky, A.J., Paul, S.M. (1985) [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem., 45, 1062-1070.
50. Sher, P.K., Reinberg, Y. (1996) Successful treatment of giggle incontinence with methylphenidate. J. Urol., 156, 656-658.
51. Sitte, H.H., Huck, S., Reither, H., Boehm, S., Singer, E.A., Pifl, C. (1998) Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem., 71, 1289-1297.
52. Sonders, M.S., Zhu, S.J., Zahniser, N.R., Kavanaugh, M.P., Amara, S.G. (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci., 17, 960-974.
53. Spencer, T., Wilens, T., Biederman, J., Faraone, S.V., Ablon, J.S., Lapey, K. (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch. Gen Psychiatry, 52, 434-443.
54. Staley, J.K., Basile, M., Flynn, D.D., Mash, D.C. (1994) Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J. Neurochem., 62, 549-556.
55. Swanson, J.M., Volkow, N.D. (2002) Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav. Brain Res., 130, 73-78.
56. Thomas, D.M., Francescutti-Verbeem, D.M., Kuhn, D.M. (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem., 105, 605-616.
57. Tissari, A.H., Atzori, L., Galdieri, M.T. (1983) Inhibition of dopamine synthesis in striatal synaptosomes by lisuride: stereospecific reversal by (-)-sulpiride. Naunyn Schmiedebergs Arch. Pharmacol., 322, 89-91.
58. Truong, J.G., Newman, A.H., Hanson, G.R., Fleckenstein, A.E. (2004) Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur. J. Pharmacol., 504, 27-32.
59. Truong, J.G., Wilkins, D.G., Baudys, J., Crouch, D.J., Johnson-Davis, K.L., Gibb, J.W., Hanson, G.R., Fleckenstein, A.E. (2005) Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J. Pharmacol. Exp. Ther., 314, 1087-1092.
60. Vigano, A., Watanabe, S., Bruera, E. (1995) Methylphenidate for the management of somatization in terminal cancer patients. J. Pain Symptom Manage., 10, 167-170.
61. Volkow, N.D., Fowler, J.S., Wang, G., Ding, Y., Gatley, S.J. (2002) Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord., 6, S31-43.
62. Volkow, N.D., Wang, G., Fowler, J.S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y., Gatley, S.J., Gifford, A., Franceschi, D. (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci., 21, RC121.
63. Volkow, N.D., Wang, G.J., Fowler, J.S., Gatley, S.J., Logan, J., Ding, Y.S., Hitzemann, R., Pappas, N. (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry, 155, 1325-1331.
64. Volz, T.J., Bjorklund, N.L., Schenk, J.O. (2005) Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum. Synapse, 57, 175-178.
65. Volz, T.J., Farnsworth, S.J., King, J.L., Riddle, E.L., Hanson, G.R., Fleckenstein, A.E. (2007) Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J. Pharmacol. Exp. Ther., 323, 738-745.
66. Volz, T.J., Fleckenstein, A.E., Hanson, G.R. (2007) Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction, 102, 44-48.
67. Volz, T.J., Hanson, G.R., Fleckenstein, A.E. (2006) Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse, 60, 474-477.
68. Volz, T.J., Hanson, G.R., Fleckenstein, A.E. (2006) Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J. Neurosci. Methods, 155, 109-115.
69. Volz, T.J., Hanson, G.R., Fleckenstein, A.E. (2007) The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J. Neurochem., 101, 883-888.
70. Volz, T.J., Kim, M., Schenk, J.O. (2004) Covalent and noncovalent chemical modifications of arginine residues decrease dopamine transporter activity. Synapse, 52, 272-282.
71. Volz, T.J., Schenk, J.O. (2005) A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse, 58, 72-94.
72. Wagner, G.C., Ricaurte, G.A., Seiden, L.S., Schuster, C.R., Miller, R.J., Westley, J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res., 181, 151-160.
73. Wallace, L.J., Connell, L.E. (2008) Mechanisms by which amphetamine redistributes dopamine out of vesicles: A computational study. Synapse, 62, 370-378.
74. Wayment, H., Meiergerd, S.M., Schenk, J.O. (1998) Relationships between the catechol substrate binding site and amphetamine, cocaine, and mazindol binding sites in a kinetic model of the striatal transporter of dopamine in vitro. J. Neurochem., 70, 1941-1949.
75. Wayment, H.K., Deutsch, H., Schweri, M.M., Schenk, J.O. (1999) Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J. Neurochem., 72, 1266-1274.
76. White, J.C., Christensen, J.F., Singer, C.M. (1992) Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. J. Clin. Psychiatry, 53, 153-156.
77. Xie, T., McCann, U.D., Kim, S., Yuan, J., Ricaurte, G.A. (2000) Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci., 20, 7838-7845.
78. Zaczek, R., Culp, S., De Souza, E.B. (1991) Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J. Pharmacol. Exp. Ther., 257, 830-835.